ライフサイエンスコーパス: cardiovascular drug

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ting enzyme (ACE) inhibitors are widely used cardiovascular drugs.

2 -years) but no more or less likely to switch cardiovascular drugs.

3 monly used herbs and their interactions with cardiovascular drugs.

4 e benefits and risks of the long-term use of cardiovascular drugs.

5 a, and developed and analyzed an Ontology of Cardiovascular Drug AEs (OCVDAE).

6 etics has expanded to study a broad range of cardiovascular drugs and has become a mainstream researc

7 ble responsiveness and toxicity to important cardiovascular drugs and highlight recent developments i

8 gin, sex, history of cardiovascular disease, cardiovascular drugs, and cardiovascular risk factors.

9 pressant, antineoplastic, antimicrobial, and cardiovascular drugs, as well as oral contraceptive ster

10 e the same therapeutic profile as the parent cardiovascular drug but lacking its metabolic liability

11 During the last years, two new cardiovascular drug classes, namely inhibitors of DPP IV

12 We focus on 4 commonly used cardiovascular drug classes: aspirin, statins, beta-bloc

13 ene variants that modulate responsiveness to cardiovascular drugs continue to be discovered and valid

14 With increased usage of cardiovascular drugs (CVDs) for treating cardiovascular

15 den of cardiovascular disease, investment in cardiovascular drug development has stagnated over the p

16 d consensus on improving the environment for cardiovascular drug development, stakeholders from acade

17 s to delineate the current adverse trends in cardiovascular drug development, understand the key issu

18 research offer promise to greatly facilitate cardiovascular drug development.

19 serves as a model for the next generation of cardiovascular drug development.

20 We compared rates of cardiovascular drug discontinuation, drug switching, and

21 the coverage gap were at increased risk for cardiovascular drug discontinuation; however, the impact

22 l as effective and innovative H2S donors for cardiovascular drug discovery.

23 Some cardiovascular and non-cardiovascular drugs frequently cause excessive prolonga

24 Certain cardiovascular drugs have adverse effects on glucose hom

25 P-gp substrates and/or inhibitors, and many cardiovascular drugs have recently been observed to have

26 In vivo interaction of the cardiovascular drugs metoprolol (beta-blocker) and ramip

27 The risk factor potency of cardiovascular drugs on the severity of anaphylaxis in p

28 cations where concentrations of antibiotics, cardiovascular drugs, painkillers, contrast media, and a

29 Cardiovascular drugs show increasing molecular weight wi

30 y and toxicity of other important classes of cardiovascular drugs, such as beta-blockers, is becoming

31 injury, implicating macrophage mPGES-1 as a cardiovascular drug target.

32 lerotic heart disease, making it a promising cardiovascular drug target.

33 Vasopeptidase inhibitors are a new class of cardiovascular drug that simultaneously inhibit both neu

34 wall remodeling can be antagonized by common cardiovascular drugs that act in part by inhibiting vasc

35 w the interactions among commonly prescribed cardiovascular drugs that are P-gp substrates and observ

36 n addition to existing antihyperglycemic and cardiovascular drug therapy.

37 diligent in promoting adherence to guideline cardiovascular drug therapy.

38 nal debate; evidence regarding its impact on cardiovascular drug use and health outcomes is needed.

39 Increased cardiovascular drug use and resulting health improvement

40 baseline, NYHA class, LV EF, age, and use of cardiovascular drugs were similar between the 2 groups.

41 Cardiovascular drugs with narrow therapeutic indexes (e.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。